Page 49 - Libro de Ponencias Congres SEHH-SETH 2017

4. Chen CC, Gau JP, Chou HJ, You JY, Huang CE, Chen YY, et al. Frequencies, clinical characteristics, and outcome of somatic CALR mutations in JAK2- unmutated essential thrombocythemia. Ann Hematol. 2014;93:2029-36.
5. Tefferi A. Mutant molecules of interest in myeloproliferative neoplasms: intro- duction. Acta Haematol. 2008;119:192-3.
6. Álvarez-Larrán A, Cervantes F, Pereira A, Arellano-Rodrigo E, Pérez-Andreu V, Hernández-Boluda JC, et al. Observation versus antiplatelet therapy as
primary prophylaxis for thrombosis in low-risk essential thrombocythemia.
Blood. 2010;116:1205-10. quiz 1387.
7. Barbui T, Finazzi G, Carobbio A, Thiele J, Passamonti F, Rumi E, et al. Devel-
opment and validation of an International Prognosis Score of Thrombosis in World Health Organization-essential thrombocytemia (IPSET-thrombosis). Blood. 2012;120(25): 5128-33.
LIX Congreso Nacional de la Sociedad Española de Hematología y Hemoterapia / Ponencias
49